The combined treatment significantly inhibited tumor growth by continuously eliminating Foxp3+ regulatory T cells and myeloid-derived suppressive cells, dramatically decreasing the infiltration of tumor-infiltrating lymphocytes, and reducing the expression of PD-1 and PD-L1 [145]. The gene discussed is PDCD1; the disease is neoplasm.